^
Association details:
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Melanoma)
New
Excerpt:
Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Excerpt:
...Confirmed diagnosis of a malignancy harbouring any actionable BRAF V600 mutation using an analytically validated sequencing technique (result does...
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Sustained Tumor Control With MAPK Inhibition in BRAF V600–Mutant Adult Glial and Glioneuronal Tumors

Published date:
06/04/2021
Excerpt:
Twenty-eight adults with recurrent or disseminated BRAF V600-mutant gangliogliomas (n=9), pleomorphic xanthoastrocytomas (n=9), and diffuse gliomas...15 combinations of RAFi/MEKi [vemurafenib+cobimetinib (n=5), dabrafenib+trametinib...Eleven patients achieved a partial or complete response (11/28, 39%), with a median reduction of -78% in their tumor burden....Five patients were rechallenged with RAFi/MEKi at progression, with novel tumor responses in two....study highlights the clinical benefits of RAFi/MEKi in adult patients with BRAF-mutant GGNT...
DOI:
https://doi.org/10.1212/WNL.0000000000012330